Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European organization for research and treatment of cancer, gastrointestinal tract cancer cooperative group)

• Published in: European journal of cancer (1990) Vol. 32; no. 8; pp. 1432 - 1433
• Main Authors: Rougier, Ph, Van Pottelsberghe, C., Kok, T., Paillot, B., Wagener, T., De Greve, J., Fabri, M.C., Gerard, B., Van Glabbeke, M., Bleiberg, H., the, EORTC-GITCCG
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 01.07.1996; Elsevier
• Subjects: Adult; Aged; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Combined treatment; Female; fotemustine; gastric cancer; Gastroenterology. Liver. Pancreas. Abdomen; Hematologic Diseases - chemically induced; Humans; Male; Medical sciences; Middle Aged; Nitrosourea Compounds - adverse effects; Nitrosourea Compounds - therapeutic use; Organophosphorus Compounds - adverse effects; Organophosphorus Compounds - therapeutic use; phase II trial; Stomach Neoplasms - drug therapy; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Treatment Outcome; Treatment. General aspects; Tumors; fotemustine; gastric cancer; phase II trial; Antineoplastic agent; Human; Stomach; Phase II trial; Digestive diseases; Malignant tumor; Gastric disease
• ISSN: 0959-8049; 1879-0852
• DOI: 10.1016/0959-8049(96)00088-3

Fotemustine activity was evaluated in 26 patients, mostly pretreated, with advanced gastric cancer. Its main toxicity was haematological with grade 3–4 neutropenia in 32% and grade 3–4 thrombocytopenia in 50% of the patients, complicated by 2 toxicity-related deaths due to haemorrhage. No complete or partial responses were observed in the 26 eligible patients and median survival was only 11 weeks. Fotemustine therefore has no activity in advanced gastric cancer.